Evidence map›Paper›PMID 34102017›Full record

ArticleJournal of cachexia, sarcopenia and muscle2021

Severe loss of mechanical efficiency in COVID-19 patients.

Eulogio Pleguezuelos, Amin Del Carmen, Gemma Llorensi, Jessica Carcole, Paula Casarramona, Eva Moreno, Pilar Ortega, Mateo Serra-Prat, Elisabet Palomera, Marc M Miravitlles and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 5 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 5 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Evaluation of myocardial work and exercise capacity in patients recovered from the severe form of COVID-19.International journal of cardiology. Cardiovascular risk and prevention · 2024
    Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Eulogio PleguezuelosPhysical Medicine and Rehabilitation Department, Hospital de Mataró, Mataró, Spain.
Amin Del CarmenPhysical Medicine and Rehabilitation Department, Hospital de Mataró, Mataró, Spain.
Gemma LlorensiPhysical Medicine and Rehabilitation Department, Hospital de Mataró, Mataró, Spain.
Jessica CarcolePhysical Medicine and Rehabilitation Department, Hospital de Mataró, Mataró, Spain.
Paula CasarramonaPhysical Medicine and Rehabilitation Department, Hospital de Mataró, Mataró, Spain.
Eva MorenoPhysical Medicine and Rehabilitation Department, Hospitalet General Hospital, L'Hospitalet de Llobregat, Spain.
Pilar OrtegaPneumology Department, Hospital de Mataró, Mataró, Spain.
Mateo Serra-PratResearch Unit, Consorci Sanitari del Maresme, Mataró, Spain.
Elisabet PalomeraResearch Unit, Consorci Sanitari del Maresme, Mataró, Spain.
Marc M MiravitllesPneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron Barcelona Hospital Campus, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.
Joan Carles YebenesCritical Care Department, Hospital de Mataró, Mataró, Spain.
Ramón BoixedaDepartment of Internal Medicine, Hospital de Mataró, CSDM, Mataró, Spain.
Lluis CampinsDepartment of Pharmacy, Hospital de Mataró, CSdM, Mataró, Spain.
Koldo Villelabeitia-JaureguizarPhysical Medicine and Rehabilitation Department, Infanta Elena University Hospital, Valdemoro, Spain.
Manuel Vicente Garnacho-CastañoGRI-AFIRS, School of Health Sciences, TecnoCampus, Universitat Pompeu Fabra, Mataró, Spain.ORCID 0000-0003-3180-4629
Hospital de Mataró · ESMaresme Health Consortium · ESUniversitat Pompeu Fabra · ESAjuntament de L’Hospitalet · ESCentro de Investigación Biomédica en Red de Enfermedades Respiratorias · ESHospital Universitario Infanta Leonor · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is limited information about the impact of coronavirus disease (COVID-19) on the muscular dysfunction, despite the generalized weakness and fatigue that patients report after overcoming the acute phase of the infection. This study aimed to detect impaired muscle efficiency by evaluating delta efficiency (DE) in patients with COVID-19 compared with subjects with chronic obstructive pulmonary disease (COPD), ischaemic heart disease (IHD), and control group (CG).

methodsA total of 60 participants were assigned to four experimental groups: COVID-19, COPD, IHD, and CG (n = 15 each group). Incremental exercise tests in a cycle ergometer were performed to obtain peak oxygen uptake (VO

resultsA lower DE was detected in patients with COVID-19 and COPD compared with those in CG (P ≤ 0.033). However, no significant differences were observed among the experimental groups with diseases (P > 0.05). Lower VO

conclusionsPatients with COVID-19 showed marked mechanical inefficiency similar to that observed in COPD and IHD patients. Patients with COVID-19 and COPD showed a significant decrease in power output compared to IHD during pedalling despite having similar response in VO

Indexed as

COVID-19ExerciseExercise TestHeart DiseasesHumansIschemiaLungMaleMiddle AgedOxygen ConsumptionPulmonary Disease, Chronic ObstructiveResistance TrainingRespiratory Function TestsSARS-CoV-2Cardiopulmonary exercise testCOPDIschaemic heart diseaseMuscular dysfunctionSARS-CoV-2

Identifiers

PMID34102017
PMCPMC8242734
OpenAlexW3167017413

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.